Work

JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series

Year: 2026

Type: article

Abstract: Background: Eczematous eruption (EE) is a paradoxical adverse event during interleukin-17A (IL-17A) inhibitor therapy for psoriasis and may require modification or discontinuation of biologic therapy. However, evidence guiding its management remains limited. Methods: We retrospectively reviewed 13 patients with psoriasis who developed EE during IL-17A inhibitor therapy and subsequently received selective Janus kinase 1 inhibitors (JAK1i; upadacitinib, n=11; abrocitinib, n=2). Results: JAK1i treatment resulted in rapid clinical improvement, with mean Eczema Area and Severity Index (EASI) scores decreasing from 14.7 to 3.0 and pruritus visual analogue scale scores from 9.1 to 2.2 after 4 weeks; all patients showed marked clinical improvement by week 8. During a median follow-up of 68 weeks from JAK1i initiation, subsequent psoriasis treatment was individualized according to disease course, with heterogeneous subsequent treatment strategies across patients. Conclusion: These findings support the potential use of selective JAK1 inhibitors for rapidly controlling IL-17A inhibitor-associated EE, with subsequent psoriasis management individualized according to the clinical course.

Source: Psoriasis Targets and Therapy

DOI: 10.2147/ptt.s640212

Authors: Li Zhang, Jingwen Wu, Jie Zheng, Lihong Chen, Youcong Wang, Xia Li

Institutions: Shanghai Jiao Tong University, Ruijin Hospital

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,320